Friday, 16 October 2026European Markets

ARCELORMITTAL SA And ROBERTET Have A High Dividend Yield And Return On Equity In The Basic Materials Sector.

Loading stream...

(vianews) - arcelormittal sa (mt.as) is among this list of stock assets with the highest dividend rate and return on equity on the basic materials sector.

financial asset price forward dividend yield return on equity
arcelormittal sa (mt.as) €24.39 1.43% 17.84%
robertet (rbt.pa) €864.00 0.92% 14.34%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. arcelormittal sa (mt.as)

1.43% forward dividend yield and 17.84% return on equity

arcelormittal s.a., together with its subsidiaries, operates as integrated steel and mining companies in the americas, europe, asia, and africa. it offers semi-finished flat products, including slabs; finished flat products comprising plates, hot- and cold-rolled coils and sheets, hot-dipped and electro-galvanized coils and sheets, tinplate, and color coated coils and sheets; semi-finished long products, such as blooms and billets; finished long products consisting of bars, wire-rods, structural sections, rails, sheet piles, and wire-products; and seamless and welded pipes and tubes. the company also provides mining products, such as iron ore lumps, fines, concentrates, pellets, and sinter feeds; and coking and pulverized coal injections coal. it sells its products to various customers in the automotive, appliance, engineering, construction, energy, and machinery industries through a centralized marketing organization, as well as distributors. the company has iron ore mining activities in brazil, bosnia, canada, kazakhstan, liberia, mexico, south africa, and ukraine; and coal mining activities in kazakhstan. arcelormittal s.a. was founded in 1976 and is headquartered in luxembourg city, luxembourg.

earnings per share

as for profitability, arcelormittal sa has a trailing twelve months eps of €9.21.

pe ratio

arcelormittal sa has a trailing twelve months price to earnings ratio of 2.65. meaning, the purchaser of the share is investing €2.65 for every euro of annual earnings.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 17.84%.

sales growth

arcelormittal sa's sales growth is negative 28.9% for the present quarter and negative 23.4% for the next.

volatility

arcelormittal sa's last week, last month's, and last quarter's current intraday variation average was a negative 2.00%, a negative 0.33%, and a positive 2.01%.

arcelormittal sa's highest amplitude of average volatility was 2.76% (last week), 1.54% (last month), and 2.01% (last quarter).

revenue growth

year-on-year quarterly revenue growth declined by 18.8%, now sitting on 79.84b for the twelve trailing months.

more news about arcelormittal sa.

2. robertet (rbt.pa)

0.92% forward dividend yield and 14.34% return on equity

robertet sa produces and sells perfumes, aromas, and natural products. the company operates in three segments: raw materials, fragrances, and flavors. it also produces organic essential oils and active ingredients. the company operates in north america, europe, the asia pacific, south america, caribbean, africa, and the middle east. robertet sa was founded in 1850 and is headquartered in grasse, france.

earnings per share

as for profitability, robertet has a trailing twelve months eps of €36.49.

pe ratio

robertet has a trailing twelve months price to earnings ratio of 23.68. meaning, the purchaser of the share is investing €23.68 for every euro of annual earnings.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 14.34%.

more news about robertet.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com